3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Lung Neoplasms
13
Neoplasms
8
Melanoma
6
Neoplasm Metastasis
5
Head and Neck Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Ovarian Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Large Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Advanced Non-Small Cell Lung Cancer
2
Adenocarcinoma
2
Vaccinia
1
Uterine Neoplasms
1
Interventions
pembrolizumab
7
Ipilimumab
5
Nivolumab
4
fludarabine
3
Radiosurgery
3
Drug Therapy
3
Cyclophosphamide
3
spartalizumab
2
aldesleukin
2
Sirolimus
2
Riluzole
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Oncolytic Virotherapy
2
Counseling
2
Bupropion
2
Blood Specimen Collection
2
vofatamab
1
utomilumab
1
trastuzumab deruxtecan
1
toripalimab
1
tocilizumab
1
sargramostim
1
saracatinib
1
pertuzumab
1
pazopanib
1
liposomal doxorubicin
1
ixabepilone
1
fostamatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
cemiplimab
×
Thoracic
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled